Compare SGHT & NAUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGHT | NAUT |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 235.0M | 383.5M |
| IPO Year | 2021 | 2020 |
| Metric | SGHT | NAUT |
|---|---|---|
| Price | $4.96 | $2.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $9.08 | $4.00 |
| AVG Volume (30 Days) | 121.2K | ★ 390.6K |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.16 | 16.07 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $77,363,000.00 | N/A |
| Revenue This Year | $11.67 | N/A |
| Revenue Next Year | $10.39 | $992.86 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.11 | $0.62 |
| 52 Week High | $9.24 | $4.31 |
| Indicator | SGHT | NAUT |
|---|---|---|
| Relative Strength Index (RSI) | 56.20 | 35.64 |
| Support Level | $4.76 | $1.82 |
| Resistance Level | $5.25 | $2.30 |
| Average True Range (ATR) | 0.30 | 0.16 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 73.27 | 2.03 |
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Its products includes: Proteome Analysis System, Reagent Kits, Software and analysis.